Core Insights - Myriad Genetics has received FDA approval for the MyChoice® CDx Test as a Companion Diagnostic for Zejula® (niraparib) in patients with advanced ovarian cancer [1][4] Group 1: FDA Approval and Clinical Significance - The approval is based on final data from the PRIMA trial, where the MyChoice CDx Test was used to determine homologous recombination deficiency (HRD) status in advanced ovarian cancer patients [2] - MyChoice CDx is the only FDA-approved test in the U.S. for identifying HRD-positive patients eligible for Zejula treatment, utilizing next-generation sequencing technology to assess BRCA1/2 genes and tumor genomic instability [3][6] Group 2: Importance of HRD Testing - Nearly 50% of patients with advanced ovarian cancer have HRD-positive tumors, making the identification of these patients crucial for appropriate PARP inhibitor therapy [4] - The MyChoice CDx Test can identify 34% more HRD-positive patients compared to other tests that rely solely on loss of heterozygosity [6] Group 3: Zejula Overview - Zejula is indicated for maintenance treatment in adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have HRD-positive status and have responded to first-line platinum-based chemotherapy [7][8]

Core Insights - Illumina has launched TSO 500 v2, an advanced assay that enhances tumor profiling capabilities with built-in HRD detection, faster turnaround times, and reduced tissue requirements [1][2] - The assay assesses hundreds of genes and immuno-oncology biomarkers, facilitating personalized treatment and improving patient outcomes when used early in cancer diagnosis [1] Product Enhancements - TSO 500 v2 includes HRD status analysis at no additional cost, utilizing a Genomic Instability Scoring (GIS) algorithm from Myriad Genetics, expanding research into HRD biomarkers across various cancer types [2] - The new workflow is designed to be faster and more efficient, with improved accuracy compared to previous solutions from other vendors [4] - The updated packaging and kit configuration reduce the number of boxes and tubes, enhancing user experience and minimizing errors during the workflow [5] Workflow Efficiency - The streamlined workflow reduces turnaround time and hands-on time, with sensitive variant calling and better coverage of difficult genomic regions [7] - New kit configurations feature 50% less packaging and 70% fewer tubes, improving sustainability and usability with a color-coded tubing system [7] - Integrated data analysis is supported by DRAGEN™ secondary analysis and Illumina Connected Insights, with compatibility across various sequencers [7] Strategic Partnerships - Illumina has partnered with Pillar BioSciences to offer targeted molecular profiling tests, including the upcoming Pillar oncoReveal CDx IVD kit [8]